Pharma: Page 2
-
Permission granted by Bristol-Myers Squibb
Ahead of its upcoming decision date, a competitor takes aim at KarXT
The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.
By Kelly Bilodeau • June 25, 2024 -
Jens Schluete via Getty Images
Q&ACan Moderna’s COVID-flu combo shot improve flagging vaccination rates?
A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.
By Michael Gibney • June 25, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Christoph Burgstedt via Getty Images
Q&A // First 90 DaysAfter an obesity deal with Novo, Omega’s new business head is on the hunt for more partners
With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.
By Amy Baxter • June 24, 2024 -
Stock via Getty Images
3 windows of opportunity in women’s health
Despite a recent surge of interest, the femtech and women’s health markets are far from reaching their full potential.
By Alexandra Pecci • June 21, 2024 -
Love Employee via Getty Images
New data showcase promise, growing pains of CAR-T in autoimmune disease
One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
By Ben Fidler • June 20, 2024 -
Stock via Getty Images
NIH-funded trials fall flat on diversity goals
Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.
By Amy Baxter • June 20, 2024 -
iStock via Getty Images
Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’
Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.
By Michael Gibney • June 18, 2024 -
digicomphoto via Getty Images
The hunt for the brain’s biomarkers
How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease.
By Kelly Bilodeau • June 17, 2024 -
Joe Raedle via Getty Images
Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll
While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.
By Meagan Parrish • June 14, 2024 -
Dr_Microbe via Getty Images
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.
By Michael Gibney • June 13, 2024 -
Stock via Getty Images
Behind the powerful computations, AI’s role in pharma is still beset by challenges
Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.
By Amy Baxter • June 12, 2024 -
Sarah Silbiger via Getty Images
FDA’s platform designation aims to ease R&D pain points
A new program creates approval pathways for multiple drugs developed on the same platform.
By Amy Baxter • June 11, 2024 -
Christopher Furlong via Getty Images
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.
By Michael Gibney • June 11, 2024 -
Permission granted by Bristol-Myers Squibb
Behind Big Pharma’s layoffs — is there an end in sight?
A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?
By Kelly Bilodeau • June 10, 2024 -
Stock via Getty Images
Pharma’s R&D gamble: picking pipeline winners in a risky field
How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.
By Meagan Parrish • June 7, 2024 -
Permission granted by City of Hope
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Christopher Furlong via Getty Images
What’s in a drug name? More than you might think.
From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.
By Alexandra Pecci • June 4, 2024 -
Courtesy of Merck & Co.
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024 -
Justin Sullivan via Getty Images
After two Big Pharma deals, Nimbus looks to keep the hits coming
With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.
By Kelly Bilodeau • June 3, 2024 -
Stock via Getty Images
Q&AIn an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
By Amy Baxter • June 3, 2024 -
Permission granted by Cravath, Swaine & Moore
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.
By Michael Gibney • May 30, 2024 -
stock via Getty Images
FTC request may signal trouble for Novo/Catalent deal
As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.
By Kelly Bilodeau • May 29, 2024 -
Stock via Getty Images
As weight loss booms, drugmakers look for an edge with oral options
Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.
By Amy Baxter • May 28, 2024 -
Stock via Getty Images
Where competition is heating up in pharma
The stage is set for potential blockbuster-level showdowns targeting these three indications.
By Meagan Parrish • May 24, 2024 -
Dan Kitwood/Getty Images via Getty Images
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.
By Michael Gibney • May 23, 2024
Previous
